Literature DB >> 6797725

Influence of prolactin and growth hormone on rat mammary tumors induced by N-nitrosomethylurea.

D P Rose, J J Noonan.   

Abstract

The effects of hypophysectomy and prolactin-suppressing drugs on the growth of mammary tumors induced in Sprague-Dawley rats by N-nitrosomethylurea and dimethylbenz(a)anthracene were compared. The influence of ovine prolactin and growth hormone administration on N-nitrosomethylurea-induced tumors was also studied in hypophysectomized animals. After hypophysectomy, all 13 tumors induced in 13 rats by N-nitrosomethylurea underwent regression, as did ten of 12 induced by dimethylbenz(a)anthracene. There were no new tumors. Pergolide mesylate, a long-acting ergoline derivative, was given in a dose of 80 micrograms twice daily by s.c. injection for 28 days. Only three of 12 N-nitrosomethylurea-induced tumors regressed, while four became static. However, only two new tumors developed in the 12 pergolide-treated rats, compared to 11 in the 12 untreated controls. Bromocriptine mesylate, at ten times the pergolide dose, was even less effective; one of 16 tumors regressed, two became static, and eight new tumors appeared in the 16 rats. In contrast, eight of 12 dimethylbenz(a)anthracene-induced tumors regressed during pergolide therapy, two became static, and there was only one new tumor among the 12 rats. Prolactin, 1 mg twice daily for 7 days by s.c. injection, was given to another eight rats bearing 11 N-nitrosomethylurea-induced tumors, commencing 7 days after hypophysectomy. Regression of five tumors borne by four rats was reversed but resumed when treatment was stopped. Regression of five tumors in the other four animals was arrested without regrowth; the sixth became inpalpable. All of these six grew rapidly when growth hormone, 2 mg twice daily, was administered in addition to prolactin.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6797725

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  The myelodysplastic syndromes.

Authors:  A Jacobs
Journal:  Br Med J (Clin Res Ed)       Date:  1987-08-29

2.  Hormone prevention of mammary carcinogenesis by norethynodrel-mestranol.

Authors:  I H Russo; J Frederick; J Russo
Journal:  Breast Cancer Res Treat       Date:  1989-10       Impact factor: 4.872

Review 3.  Considering GH replacement for GH-deficient adults with a previous history of cancer: a conundrum for the clinician.

Authors:  Kevin C J Yuen; Anthony P Heaney; Vera Popovic
Journal:  Endocrine       Date:  2016-01-05       Impact factor: 3.633

4.  Neoplastic and nonneoplastic lesions in aging female rats with special reference to the functional morphology of the hyperplastic and neoplastic changes in the pituitary gland.

Authors:  M A Attia
Journal:  Arch Toxicol       Date:  1985-06       Impact factor: 5.153

5.  Estrone sulfate: a potential source of estradiol in human breast cancer tissues.

Authors:  S J Santner; D Leszczynski; C Wright; A Manni; P D Feil; R J Santen
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

6.  Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: potential involvement of antiestrogenic mechanisms in vivo.

Authors:  D E Blask; D B Pelletier; S M Hill; A Lemus-Wilson; D S Grosso; S T Wilson; M E Wise
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

7.  From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents.

Authors:  A Corbin
Journal:  Yale J Biol Med       Date:  1982 Jan-Feb
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.